Equities analysts expect that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will post earnings per share of ($0.07) for the current quarter, according to Zacks. Four analysts have made estimates for Enanta Pharmaceuticals’ earnings. The highest EPS estimate is $0.20 and the lowest is ($0.30). Enanta Pharmaceuticals reported earnings per share of $0.61 during the same quarter last year, which would indicate a negative year over year growth rate of 111.5%. The business is expected to announce its next quarterly earnings results on Tuesday, May 14th.
According to Zacks, analysts expect that Enanta Pharmaceuticals will report full year earnings of $1.52 per share for the current financial year, with EPS estimates ranging from $0.81 to $2.13. For the next financial year, analysts expect that the firm will post earnings of ($1.04) per share, with EPS estimates ranging from ($1.64) to ($0.53). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Wednesday, February 6th. The biotechnology company reported $1.25 EPS for the quarter, missing the Zacks’ consensus estimate of $1.46 by ($0.21). The firm had revenue of $69.89 million during the quarter, compared to the consensus estimate of $71.27 million. Enanta Pharmaceuticals had a net margin of 36.19% and a return on equity of 22.78%. The firm’s revenue was up 83.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.59 EPS.
ENTA has been the topic of a number of research analyst reports. Zacks Investment Research raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, November 19th. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, November 20th. Oppenheimer set a $100.00 price objective on shares of Enanta Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, November 27th. Finally, Berenberg Bank started coverage on shares of Enanta Pharmaceuticals in a research report on Thursday, December 13th. They set a “hold” rating and a $80.00 target price for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $100.00.
ENTA traded down $1.11 during trading on Tuesday, reaching $88.78. The stock had a trading volume of 12,785 shares, compared to its average volume of 257,179. The stock has a market cap of $1.76 billion, a PE ratio of 25.64 and a beta of 1.27. Enanta Pharmaceuticals has a one year low of $64.08 and a one year high of $127.77.
A number of large investors have recently modified their holdings of the business. PNC Financial Services Group Inc. grew its holdings in Enanta Pharmaceuticals by 64.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 634 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 249 shares during the period. Bank of Montreal Can boosted its stake in Enanta Pharmaceuticals by 33.0% in the fourth quarter. Bank of Montreal Can now owns 870 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 216 shares in the last quarter. Smith Asset Management Group LP acquired a new position in Enanta Pharmaceuticals in the third quarter worth $173,000. People s United Financial Inc. acquired a new position in Enanta Pharmaceuticals in the third quarter worth $212,000. Finally, Pacer Advisors Inc. acquired a new position in Enanta Pharmaceuticals in the third quarter worth $230,000. 87.23% of the stock is owned by institutional investors.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
See Also: What is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.